Acumen Pharmaceuticals, Inc. — Q2 2021 Form 10-Q
Reporting period: Three and six months ended June 30, 2021. The unaudited statements compare the periods with 2020. Acumen is a clinical-stage biopharmaceutical company focused on Alzheimer’s disease; ACU193, its lead and sole product candidate, is a humanized antibody targeting amyloid-beta oligomers. The company began a Phase 1 trial in early Alzheimer’s patients in April 2021 and has no products approved for sale.
Financial performance and position
Amounts below are in U.S. dollars; financial statement figures are rounded to millions unless otherwise indicated.
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Grant and other revenue | $0 | $0.151 million | $0 | $0.377 million |
| Research and development expense | $2.254 million | $1.927 million | $4.832 million | $3.977 million |
| General and administrative expense | $1.187 million | $0.259 million | $2.402 million | $0.481 million |
| Net loss | $61.358 million | $2.035 million | $88.355 million | $4.080 million |
| Net loss per common share, basic and diluted | $141.93 | $4.86 | $207.52 | $9.73 |
The unusually large 2021 net losses primarily reflect noncash fair-value expense on preferred-stock financing instruments: $57.940 million in Q2 and $81.157 million for the first half. Excluding this accounting charge, operating losses were $3.441 million for Q2 and $7.234 million for the first half; these are not company-reported adjusted earnings measures. The company reported no product sales and no meaningful basis for assessing product margins.
- Cash and liquidity: Cash and cash equivalents were $68.812 million at June 30, 2021, versus $43.777 million at December 31, 2020. Working capital was $66.1 million. Cash equivalents included approximately $36.8 million in money market securities.
- Cash flow, six months: Operating activities used $6.634 million; investing activities used $6,000; financing activities provided $31.675 million. Cash increased by $25.035 million from year-end.
- Debt and liabilities: The balance sheet reported $4.518 million of total liabilities, principally accounts payable and accrued expenses. The filing does not report a debt balance. Preferred stock is presented separately as mezzanine equity, not debt.
- Funding after period-end: The July 2021 IPO raised $168.6 million net of underwriting discounts, commissions and offering expenses. Management said cash on hand at June 30 plus IPO proceeds should fund operating and capital needs at least through 2024, based on assumptions that could prove incorrect.
Changes versus the prior comparable period
- Revenue from the NIH grant ceased to be recognized in the first half of 2021, compared with $377,000 in the first half of 2020; the company said the grant had been fully recognized by year-end 2020.
- First-half R&D expense rose $855,000, mainly from higher CRO and personnel costs, partly offset by lower drug-safety testing, consulting and materials costs. G&A rose $1.921 million, mainly from public-company preparation accounting costs and additional personnel.
- First-half net loss increased by $84.275 million, driven chiefly by the fair-value expense on the Series B tranche rights and Series A-1 preferred warrant liabilities. The instruments were settled or reclassified upon the June financing closing and warrant exercise; they had no remaining balance at June 30.
- Cash increased following the June closing of the second Series B tranche, which generated $30.0 million gross, along with warrant exercises. In July, the IPO and conversion of preferred shares materially changed the company’s capital structure and common-share count.
Outlook, commentary and risks
- Acumen expects operating expenses and losses to increase as it advances ACU193, conducts clinical trials, builds clinical and corporate capabilities, and incurs public-company costs. It gave no specific revenue, earnings or expense guidance.
- The Phase 1 trial was planned to enroll 62 patients. The filing emphasizes that early-stage results may not predict later trials and that development, regulatory approval and commercialization are uncertain.
- Management reported no material business impact from COVID-19 to date, but warned that the pandemic could disrupt clinical sites, enrollment, suppliers, manufacturing and timelines.
- The FDA had placed the initial ACU193 IND submission on clinical hold pending additional nonclinical tissue cross-reactivity work; after that work, the company was permitted to initiate the Phase 1 trial. A change in ACU193 storage conditions and contract manufacturer was submitted to the FDA in an IND amendment in April 2021.
- Key risks include dependence on ACU193, uncertain Alzheimer’s drug development, clinical and regulatory failure, reliance on CROs and contract manufacturers, competition, financing needs, and intellectual-property protection. The company said it has no committed external funding source and may need additional capital.
- The company reported no material legal proceedings. Lease obligations at June 30 were approximately $332,000 in future minimum payments.
- Management concluded disclosure controls were effective as of June 30. Separately, the risk-factor discussion says a material weakness in internal control over financial reporting remained, relating to segregation of accounting duties; planned remediation included hiring accounting staff and upgrading systems.
Important facts for investors to verify
- Progress, enrollment and safety findings from the ACU193 Phase 1 trial, and the timing and content of future clinical updates.
- Whether the company’s cash-runway estimate through 2024 remains valid as trial and public-company costs develop.
- The effect of the IPO, preferred-stock conversion, warrant exercise and equity plans on fully diluted share count and potential dilution.
- How much of reported losses reflects recurring operating costs versus noncash preferred-instrument fair-value accounting, and whether comparable future charges arise.
- Whether the disclosed material weakness is remediated and whether internal controls remain effective as a newly public company.
- Any clinical, manufacturing, regulatory or COVID-related delays, and the status of the FDA amendment concerning manufacturing changes.